IMNM
Immunome Inc

2,020
Loading...
Loading...
News
all
press releases
Immunome Stock Rises After Craig-Hellum Initiates Coverage With $26 Price Target: Here’s Why The Analyst Sees An ‘Attractive Entry Point’
Craig-Hellum’s price target of $26 represents an upside of about 165% from the stock’s closing price on Thursday.
Stocktwits·7d ago
News Placeholder
More News
News Placeholder
Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates
Immunome (IMNM) delivered earnings and revenue surprises of +3.85% and +62.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Voyager Therapeutics (VYGR) Reports Q2 Loss, Lags Revenue Estimates
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -18.75% and -55.43%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Absci Corporation (ABSI) Expected to Beat Earnings Estimates: Should You Buy?
ABSCI CORP (ABSI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·1mo ago
News Placeholder
Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue Estimates
Jazz (JAZZ) delivered earnings and revenue surprises of -34.80% and -0.26%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock?
Immunome (IMNM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Zacks·2mo ago
News Placeholder
Immunome (IMNM) Upgraded to Buy: Here's What You Should Know
Zacks·3mo ago
News Placeholder
Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High?
Zacks·3mo ago
News Placeholder
Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet
Zacks·4mo ago
News Placeholder
Immunome to Present at Upcoming March Conferences
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will participate in the following...
Business Wire·7mo ago

Latest IMNM News

View

Advertisement. Remove ads.

Advertisement. Remove ads.